N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide

This compound is a synthetic small molecule classified as an experimental biphenyl amide derivative. It is known to act as an inhibitor of mitogen‐activated protein kinase 14 (MAPK14/p38α), with reported binding affinities in the low micromolar to submicromolar range (IC₅₀ ≈ 3000 nM; K₁ ≈ 480 nM)[1][5]. The structure has been co-crystallized with p38 MAP kinase and deposited in the Protein Data Bank (PDB ID: 2ZB1), confirming its direct interaction with this target[4]. There are no approved therapeutic indications or marketed formulations for this compound; it remains a research tool for studying p38 MAPK inhibition.

Other names

N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-[1,1'-biphenyl]-4-carboxamide[1,1′‑Biphenyl]-4-carboxamide, N‑(cyclopropylmethyl)‑2′‑methyl‑5′‑(5-methyl‑1,3,4‑oxadiazol‑2‑yl)biphenyl amide 4